D-dimer and Factor VIII are Independent Risk Factors for Recurrence After Anticoagulation Withdrawal for a First Idiopathic Deep Vein Thrombosis  by Cosmi, B. et al.
Abstracts
Gregory L. Moneta, MD, Section EditorD-dimer and Factor VIII are Independent Risk Factors for Recurrence
After Anticoagulation Withdrawal for a First Idiopathic Deep Vein
Thrombosis
Cosmi B, Legnani C, Cini M. Thromb Res 2008;122:610-7.
Conclusion: Elevated levels of D-dimer and factor VIII at 30  10
days after cessation of vitamin K antagonist (VKA) therapy for a first episode
of idiopathic proximal deep venous thrombosis (DVT) are independent risk
factors for recurrent venous thromboembolism (VTE).
Summary: The optimal duration of VKA therapy after a first episode
of VTE is unknown. It appears VKA extension after unprovoked VTE can
reduce the risk of recurrent VTE but at the potential price of increased
bleeding. There is therefore intense interest in stratifying patients with
idiopathic VTE with respect to risk factors that may increase rates of
recurrence. The specific objective of this study was to assess the risk of
recurrence of VTE associated with elevated D-dimer levels and factor
VIII levels after withdrawal of VKA therapy for symptomatic idiopathic
proximal VTE.
Consecutive outpatients with the first episode of idiopathic proximal
DVT were enrolled into the study after cessation of VKA therapy. At 30 
10 days after cessation of VKA therapy, levels of D-dimer (cutoff value, 500
ng/mL) and chromogenic factor VIII, as well as inherited thrombophilias
were determined. Follow-up extended for 2 years.
Overall recurrence rate of VTE was 16.4% (55 of 336; 95% confidence
interval [CI], 13%-21%). The multivariate hazard ratio for recurrence was
2.45 (95% CI, 1.24-4.99) for abnormal D-dimer and 2.76 (95% CI, 1.57-
4.85) for factor VIII 75th percentile (2.42 /mL). The values were
adjusted for age, sex, and thrombophilia. Compared with normal levels of
D-dimer and factor VIII, the multivariate hazard ratio was 4.5 (95% CI,
1.7-12.2) for normal D-dimer levels with factor VIII2.42 U/mL, and 2.7
(95% CI, 1.2-6.6) and 7.1 (95% CI, 2.8-17.6) for abnormal D-dimer with
factor VIII, respectively, below and above 2.42 U/mL.
Comment: The appropriate length of treatment with VKA therapy for
patients with idiopathic VTE is unknown. The data suggest the longer the
treatment period with VKA, the less the recurrence rates of VTE. Of course,
VKAs are associated with increased risk of bleeding and are inconvenient for
the patient. There is therefore intense interest in stratifying risk among those
patients with idiopathic VTE. This is another study that attempts to do just
that. The percentage of patients with both normal D-dimer and factor VIII
75th percentile was 37%. This implies that at least a third of patients with
idiopathic VTE have a low risk of VTE recurrence. Larger studies are
warranted to determine if the combination of factor VIII and D-dimer
analysis can be used to tailor duration of VKA therapy after idiopathic VTE.
Drug-Eluting or Bare-Metal Stents for Acute Myocardial Infarction
Mauri L, Silbaugh TS, Garg P. N Engl J Med 2008;359:1330-42.
Conclusion: Treatment with drug-eluting stents in patients with acute
myocardial infarction (AMI) results in a decreased 2-year mortality rate and
a reduction in need for repeat revascularization procedures compared with
treatment of AMI with bare-metal stents.
Summary: The Massachusetts Department of Public Health in 2002
established a requirement that hospitals in that state providing interventional
cardiology services collect data on percutaneous coronary interventions
(PCIs). Data are collected by trained data collectors and are submitted
electronically to the Massachusetts Data Analysis Center. Analysis of this
data forms the basis of this study. The authors identify patients undergoing
PCI using coronary stents with an indication of AMI. Data were analyzed
from April 1, 2003, to September 30, 2004. The authors used a propensity-
score matching analysis on three patient groups: all patients with AMI, all
patients with AMI and ST-segment elevation, and all patients with AMI
without ST-segment elevation. Analysis was based on clinical, procedural,
hospital, and insurance information collected at the time of the PCI proce-
dure. Vital statistics records were used to determine risk of death in patients
receiving drug-eluting stents and those receiving bare-metal stents.
During the study, 7217 patients were treated for AMI, of which 4016
were treated with drug-eluting stents and 3201 with bare-metal stents.
Matched pair analysis showed the 2-year risk-adjusted mortality rates were
lower for drug-eluting stents among all patients with AMI (10.7% vs 12.8%,
P  .02). The 2-year risk-adjusted mortality rate was also lower among
patients with AMIwith ST-segment elevation (8.5% vs 11.6%, P .008) and
among patients with AMI without ST-segment elevation (12.8% vs 15.6%,
P  .04). Repeat revascularization rates in all groups were also significantly
reduced with drug-eluting stents.Comment: During the time of this study, patients with MI accounted
for 40% of coronary stent procedures in Massachusetts. Drug-eluting stents
appeared to reduce restenosis in the coronary circulation after stent treat-
ment. Previous studies have reported an association between restenosis and
risk of death forMI; therefore, the findings of the studymake inherent sense.
These data were observational, however, and although the authors tried to
make their groups comparable, there are potential confounding variables. In
particular, during the time of this study, drug-eluting stents were not
available in the same size ranges as non-drug-eluting stents. Small-vessel
stenting is associated with higher risks during follow-up and during the
procedure. Therefore, because the study was not randomized, treatment
choices may have been influenced by stent availability.
Superficial Venous Thrombosis: Prevalence of Common Genetic Risk
Factors and Their Role on Spreading to Deep Veins
Milio G, Siragusa S, Mina C, et al. Thromb Res 2008;123:194-9.
Conclusion:There is a high presence of genetic mutations (factor V Leiden,
prothrombin G20210A mutation, and 5,10-methylenetetrahydrofolate reduc-
tase [MTHFR C677T]) in patients with superficial venous thrombosis (SVT)
occurring in normal veins.
Summary: SVT that occurs in varicose veins is considered of low
clinical relevance because of the generally favorable outcome. SVT occurring
in so-called healthy veins represents only approximately 25% of all SVT. This
type of SVT is generally considered of greater clinical relevance because it has
been associated with various neoplastic conditions. It is also known that SVT
occurring in so-called healthy veins can progress into the deep system.
Depending on the study, propagation into deep veins is about 3% to 15%.
Genetic abnormalities of coagulation can also predispose to SVT. Less well
studied is whether the presence of a genetic coagulation abnormality occur-
ring in patients with SVT predisposes them to progression into the deep
system.
In this study the authors evaluated 107 patients with SVT and no other
obvious risk factors. They used ultrasound examinations to document
progression into the deep system and tested for the presence of factor V
Leiden, prothrombin G20210A mutation, and MTHFR C677T mutations.
In the patients with SVT in normal veins, factor V Leiden was present in
26.3% when the thrombus was limited to the superficial veins and was
present in 60% of SVT that extended into the deep system. Prothrombin
gene mutation was found in 7.9% of SVT limited to the superficial system
and in 20% where SVT progressed to the deep system. MTHFR C677T
mutation was found in 23.7% of patients with SVT limited to the superficial
system and in 40% where SVT progressed to the deep system. In patients
with SVT occurring in varicose veins, the presence of these abnormalities was
less common (6.7%, 4.4%, and 6.7% respectively). If, however, the SVT from
the varicose veins spread to the deep system, prevalence of genetic abnor-
malities was considerably higher (13.5% factor V Leiden mutation, 7.4%
prothrombin gene mutation, and 21.4% MTHFR C677T mutation).
Comment:This article paper provides guidance on which patients with
SVT should undergo a thrombophilia evaluation. Whereas patients with
SVT occurring in normal veins were previously recognized as having a
reasonably high incidence of genetic coagulation abnormalities, this report
points out that those patients who have SVT in varicose veins that extends
into the deep system have a significant prevalence of genetic abnormalities as
well. SVT patients appropriate for thrombophilia workup are those where
the SVT occurs in normal veins and those with SVT in varicose veins that
extends into the deep system.
Low-Dose Aspirin for Primary Prevention of Atherosclerotic Events in
Patients with Type 2 Diabetes: A Randomized Controlled Trial
Ogawa H, Nakayama M, Morimoto T, et al. JAMA 2008;30:2134-41.
Conclusion: Low-dose aspirin as primary prevention does not reduce
the risk of cardiovascular events in patients with type 2 diabetes.
Summary: In patients with previous cardiovascular events, aspirin
therapy can serve as a secondary prevention strategy. Clinical guidelines also
recommend patients with risk factors for coronary heart disease should take
aspirin for primary prevention. However, subgroup analyses of large trials of
aspirin for primary prevention have not demonstrated significant effects in
patients with diabetes. Because these analyses were subgroup analyses, it is
possible they were underpowered to demonstrate primary prevention of
cardiovascular events with aspirin in patients with diabetes.The Japanese Primary Prevention of Atherosclerosis with Aspirin for
Diabetes (JPAD) Trial is reported here. The objective was to determine
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